To Russia with love

first_imgLeeds Thomas Danby college is taking its bakery skills overseas, after securing funding to collaborate with schools in Russia.The Further Education college, which holds CoVE status for its Catering, Hospitality, Bakery and Food Manufacture provisions, has received Prime Minister’s Initiative funding to collaborate with a school in Russia, sharing ideas and good practice in baking and catering.Bakery tutors recently spent five days in Kaliningrad to establish links with the bakery and food manufacturing industries, as well as with School No 12 in Sovetsk, which the college will be working with. There were detailed talks with both local government officials and college directors on the importance of improved teaching facilities and the involvement of employers in courses taught.Staff from Leeds Thomas Danby will pay a second visit to Russia in May, when they will visit bakeries and factories. The partnership aims to assist Russian colleges in moving towards competence-based training in colleges and the workplace.last_img read more


Experimental virus drug remdesivir failed in human trial

first_imgThe summary said the Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group. Remdesivir was stopped early in 18 patients because of side effects.The authors said remdesivir was “not associated with a difference in time to clinical improvement” compared to the control.After a month, 13.9 percent of the patients on remdesivir had died compared to 12.8 percent of those in the control group. The difference is not statistically significant.The WHO told the Financial Times that the draft is undergoing peer review and was published early in error. Trials continue A spokesman for Gilead told AFP: “We believe the post included inappropriate characterizations of the study,” saying it was terminated early due to low enrollment and was therefore not statistically meaningful.”As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the spokesman added.The study does not represent the final word on the matter, and there are several large-scale trials in advanced stages that should soon provide a clearer picture.Remdesivir, which is administered intravenously, was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it. Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, who was not involved in the research, said “the trial was too small in numbers recruited” to detect either benefit or risk.But he added: “If the drug only works well when given very early after infection, it may be much less useful in practice.”Last week, Stat reported it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated.The US National Institutes for Health also reported it had proven effective in a small experiment on monkeys. Remdesivir, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly — as opposed to controlling the abnormal and often lethal autoimmune response it causes.It mimics one of the four building blocks of RNA and DNA and gets absorbed into the virus’s genome, which in turn stops the pathogen from replicating.The antimalarial drugs hydroxychloroquine and chloroquine are also being widely used on COVID-19 on a so-called “compassionate basis” pending results from large trials, with early studies decidedly mixed.Other therapies that are being studied include collecting antibodies from COVID-19 survivors and injecting them in patients, or harvesting antibodies from genetically-engineered mice that were deliberately infected. Topics :center_img The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed Thursday, dampening expectations for the closely watched drug. A draft summary went online briefly on the website of the World Health Organization (WHO) and was first reported by the Financial Times and Stat, which posted a screenshot.But Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying the data showed a “potential benefit.” last_img read more


New student consulting group to focus on startups

first_img“The actual engagements and projects that students are going to work on is going to give them real hands-on experience in the field of consulting, and not just looking at profit loss statements,” Mollo said. “It wasn’t a traditional consulting case, in the sense that it wasn’t like a very specific market entry issue with a startup, for example,” said Mollo, RISE’s vice president of engagement. “It was a lot of general issues for an architecture firm, which we weren’t that experienced in, and starting that first semester was a little difficult to know where we wanted to go.” “What’s really great is students get to not only network with these founders, they get to meet a founder of the startup to get them to become inspired,” Mollo said. “They can see what these founders are doing. Just talk with them.” “They’re going to learn not just how to show up and listen to us and take notes, but they’re going to learn how to lead and innovate and implement their ideas,” Hsu said. While RISE has only just started, its founders have big plans to expand and improve, hoping to eventually becoming the premier consulting group on campus. The organizations will work with four new start-ups this semester: TruStory, a debate and social network startup; Alpha Aerospace, a drone company run by a USC alum; We Strive, a fitness platform and Robust Choice, a win/loss analysis firm.  Getting RISE off the ground presented a few challenges as the club’s founders had to seek potential clients via LinkedIn and startup websites. CORRECTIONS: A previous version of this article misspelled TruStory’s name. It has since been updated with the correct spelling.  When then-sophomore Jonathan Lu looked through the list of consulting services group students could join at USC, he realized that none of them cater to startups, a market that he saw potential to grow.  “Long-term goal [for the organization], I’m going to guess like 40, 50 people is like a base for how many students we want,” Lu said. “Clients-wise, probably like eight a semester would be really awesome.” Lu said he hopes to eventually double the organization’s size. Each project lasts 10 weeks, allowing RISE to help its clients through the course of the semester to optimize business and pricing models and create promotional materials. Lu said RISE plans to check in with former clients after their plans are implemented to evaluate their work and progress. A lot of the learning process, however, will be taught throughout the semester as the analysts and engagement managers work with each business. RISE Consulting will partner with startup companies to create promotional materials and pricing models for clients. Jonathan Lu (far right), the president and co- founder, is pictured with members John McCubbin, Chloe Hsu and Zach Mollo. (Photo courtesy of RISE Consulting)center_img Within the organization, members are broken up into four- to five-person subgroups called engagement teams, which are headed by a manager and partnered with one of the four start-ups. This semester, the four founding members of RISE are assuming the managerial roles and leading their new members, whom they call “business analysts,” through the workshops at their weekly three-hour meetings. “Based on the semester, obviously as an up-and-coming organization, there are always problems to tackle,” Mollo said. “But the future of RISE? It’s pretty bright.” “When we first started the org, it was hard to reach out [to startups],” Mollo said. “Our brand wasn’t really that developed. We didn’t really know a lot about consulting and bringing in different founders and things like that.” Since RISE doesn’t charge its clients for the services it provides, Lu said the organization has also considered hosting funding initiatives to build a budget and pay for training and development opportunities like guest speakers. The story also incorrectly stated that TruStory is a literary startup. According to Lu, TruStory is a debate and social network startup. He then talked with his roommate Zach Mollo as well as Chloe Hsu and John McCubbin, and the group created RISE Consulting, a student organization that provides free consulting services for startups. Now in its second semester, RISE, or “Rebels, Innovators, Startups and Entrepreneurs,” is recruiting new members and accepting online applications for the first time and hopes to bring about 20 students onto its team.  Last spring, the organization’s sole client was M. Todd Architect, an architecture firm based in Brooklyn. RISE co-founders Lu, Hsu, McCubbin and Mollo, now juniors at USC, worked with the startup last spring to develop a pricing model and recommend marketing materials and promotional strategies. Along with teaching its members consulting and business skills, Hsu said the co-founders hope to teach new members how to run the organization, so that after she and her fellow co-founders  graduate in 2021, the organization can remain established. Hsu, the vice president of administration, said the organization will accept students with any level of consulting experience. The organization will hold workshops to teach new members consulting skills like presenting data, making a pitch deck and researching for their case.  “Maybe three months later, we’ll check in and ask, ‘What are the results?’” Lu said. “We always want to do that and be able to offer that advice, just so we can have those relationships going.” Mollo said over 60 students have applied and the executive board will hold group and individual interviews where applicants will work on a case to decide its new membership. The Daily Trojan regrets these errors.last_img read more